These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 29111434)

  • 1. Empirical treatment of lower urinary tract infections in the face of spreading multidrug resistance: in vitro study on the effectiveness of nitroxoline.
    Sobke A; Makarewicz O; Baier M; Bär C; Pfister W; Gatermann SG; Pletz MW; Forstner C
    Int J Antimicrob Agents; 2018 Feb; 51(2):213-220. PubMed ID: 29111434
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro activity of nitroxoline against carbapenem-resistant Acinetobacter baumannii isolated from the urinary tract.
    Fuchs F; Becerra-Aparicio F; Xanthopoulou K; Seifert H; Higgins PG
    J Antimicrob Chemother; 2022 Jun; 77(7):1912-1915. PubMed ID: 35411393
    [TBL] [Abstract][Full Text] [Related]  

  • 3.
    Fuchs F; Aldejohann AM; Hoffmann AM; Walther G; Kurzai O; Hamprecht AG
    Antimicrob Agents Chemother; 2022 Jun; 66(6):e0226521. PubMed ID: 35543103
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antimicrobial susceptibilities of urinary extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae to fosfomycin and nitrofurantoin in a teaching hospital in Taiwan.
    Liu HY; Lin HC; Lin YC; Yu SH; Wu WH; Lee YJ
    J Microbiol Immunol Infect; 2011 Oct; 44(5):364-8. PubMed ID: 21524974
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Extended-spectrum β-lactamase-producing Enterobacteriaceae: in vitro susceptibility to fosfomycin, nitrofurantoin and tigecycline.
    Al-Zarouni M; Senok A; Al-Zarooni N; Al-Nassay F; Panigrahi D
    Med Princ Pract; 2012; 21(6):543-7. PubMed ID: 22722224
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Susceptibility of carbapenemase-producing Enterobacterales (CPE) to nitroxoline.
    Fuchs F; Hamprecht A
    J Antimicrob Chemother; 2019 Oct; 74(10):2934-2937. PubMed ID: 31292653
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nitroxoline: a broad-spectrum biofilm-eradicating agent against pathogenic bacteria.
    Abouelhassan Y; Yang Q; Yousaf H; Nguyen MT; Rolfe M; Schultz GS; Huigens RW
    Int J Antimicrob Agents; 2017 Feb; 49(2):247-251. PubMed ID: 28110918
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Comparative studies on activities of antimicrobial agents against causative organisms isolated from patients with urinary tract infections (1997). I. Susceptibility distribution].
    Kumamoto Y; Tsukamoto T; Hirose T; Yokoo A; Fujime M; Fujita K; Shigeta S; Watanabe J; Igari J; Ogiwara M; Ishibashi K; Oguri T; Yoshida H; Imafuku Y; Yamaguchi K; Matsumoto T; Kashitani F; Murai M; Ooe H; Nishikawa M; Watanabe K; Kobayashi Y; Uchida H; Oka T; Mochida C
    Jpn J Antibiot; 1999 Feb; 52(2):93-129. PubMed ID: 10221177
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In-vitro activity of ceftolozane/tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae isolates recovered from hospitalized patients in Germany.
    Seifert H; Körber-Irrgang B; Kresken M;
    Int J Antimicrob Agents; 2018 Feb; 51(2):227-234. PubMed ID: 28705666
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activity of fosfomycin and comparison of several susceptibility testing methods against contemporary urine isolates.
    Hirsch EB; Raux BR; Zucchi PC; Kim Y; McCoy C; Kirby JE; Wright SB; Eliopoulos GM
    Int J Antimicrob Agents; 2015 Dec; 46(6):642-7. PubMed ID: 26498988
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antimicrobial Activities of Methanol, Ethanol and Supercritical CO2 Extracts of Philippine Piper betle L. on Clinical Isolates of Gram Positive and Gram Negative Bacteria with Transferable Multiple Drug Resistance.
    Valle DL; Cabrera EC; Puzon JJ; Rivera WL
    PLoS One; 2016; 11(1):e0146349. PubMed ID: 26741962
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antimicrobial susceptibility profiles of bacteria causing urinary tract infections in Mexico: Single-centre experience with 10 years of results.
    Lagunas-Rangel FA
    J Glob Antimicrob Resist; 2018 Sep; 14():90-94. PubMed ID: 29581074
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Comparative studies on activities of antimicrobial agents against causative organisms isolated from patients with urinary tract infections (1996). I. Susceptibility distribution].
    Kumamoto Y; Tsukamoto T; Hirose T; Yokoo A; Shigeta S; Takahashi T; Shiraiwa Y; Ogiwara M; Yoshida H; Imafuku Y; Murai M; Watanabe K; Uchida H; Kobayashi Y; Matsuda S; Fujime M; Fujita K; Igari J; Oguri T; Yamaguchi K; Matsumoto T; Kashitani F; Kaku M; Ooe H; Mochida C
    Jpn J Antibiot; 1998 Feb; 51(2):69-111. PubMed ID: 9575437
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Inhibition of bacterial adhesion of uropathogenic Escherichia coli strains by the urine of patients treated with nitroxoline].
    Karam D; Amgar A; Bourlioux P
    Pathol Biol (Paris); 1988 May; 36(5):452-5. PubMed ID: 3043342
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Comparative studies on activities on antimicrobial agents against causative organisms isolated from patients with urinary tract infections (2000). III. Secular changes in susceptibility].
    Kumamoto Y; Tsukamoto T; Hirose T; Matsukawa M; Takahashi S; Kunishima Y; Fujime M; Fujita K; Ogihara M; Ishibashi K; Igari J; Shigeta S; Oguri T; Yamaguchi K; Matsumoto T; Kashitani F; Yoshida H; Imafuku Y; Murai M; Ooe H; Nishikawa M; Watanabe K; Kobayashi Y; Uchida H; Oka T; Kitamura M; Takano Y; Matsuoka Y; Matsuda S; Sato S; Furuhama T; Kumon H; Monden K; Kohno S; Miyazaki Y; Tomono K; Aoki S; Mochida C; Hirakata Y
    Jpn J Antibiot; 2002 Oct; 55(5):568-655. PubMed ID: 12532638
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Nitroxoline - an option for the antibiotic treatment of urinary tract infections].
    Hof H; Bertsch D; Passek D; Schwarz R
    Urologe A; 2017 Feb; 56(2):167-171. PubMed ID: 27596848
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro activity of fosfomycin trometamol and other oral antibiotics against multidrug-resistant uropathogens.
    Mezzatesta ML; La Rosa G; Maugeri G; Zingali T; Caio C; Novelli A; Stefani S
    Int J Antimicrob Agents; 2017 Jun; 49(6):763-766. PubMed ID: 28390962
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Susceptibility of Escherichia coli to nitroxoline, an option for uncomplicated urinary tract infections - the first report from Croatia.
    Mareković I; Bošnjak Z; Jurić K; Ćorić M; Popović-Grle S
    J Chemother; 2018 May; 30(3):189-191. PubMed ID: 29557289
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness of selective antibiotics use in ESBL-related UTIs.
    Aththanayaka AMWGKP; Weerasinghe GGYH; Weerakkody NS; Samarasinghe SHGG; Priyadharshana U
    BMC Microbiol; 2024 Sep; 24(1):360. PubMed ID: 39306662
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rates of susceptibility of carbapenems, ceftobiprole, and colistin against clinically important bacteria collected from intensive care units in 2007: Results from the Surveillance of Multicenter Antimicrobial Resistance in Taiwan (SMART).
    Jean SS; Lee WS; Yu KW; Liao CH; Hsu CW; Chang FY; Ko WC; Chen RJ; Wu JJ; Chen YH; Chen YS; Liu JW; Lu MC; Lam C; Liu CY; Hsueh PR
    J Microbiol Immunol Infect; 2016 Dec; 49(6):969-976. PubMed ID: 25661253
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.